Active Recombinant COVID-19 Spike protein receptor binding domain (RBD), His-tagged

• Cat.No.: Spike-190V
• Product Overview: Recombinant COVID-19 Spike protein receptor binding domain (RBD) was fused to His-tag at C-terminus and expressed in human cells.

Specification

• Species: COVID-19
• Source: HEK293
• Tag: His
• Protein Length: Arg319-Phe541
• Form: Lyophilized from sterile PBS, pH 7.4
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag), the EC50 of SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag) is 20-60 ng/mL.
• Molecular Mass: The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, His Tag) consists of 234 amino acids and predicts a molecular mass of 26.54 kDa.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• Publications:
  Interfacial Water in the SARS Spike Protein: Investigating the Interaction with Human ACE2 Receptor and In Vitro Uptake in A549 Cells (2022)
  Biomaterials and oxygen join forces to shape the immune response and boost SARS-CoV-2 vaccines (2020)
  Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes (2021)
  COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice (2021)
  SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis (2021)
  Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID-19 Vaccines (2021)
  Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents (2023)